Open Access<p>Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma</p>
Author(s) -
KaiCai Liu,
Ying-Hong Hao,
WeiFu Lv,
Weidong Jia,
Cheng Ji,
Chunze Zhou,
Delei Cheng,
Shao-Bao Xu,
Zong-Gen Gao,
Mingxue Su,
Changsheng Shi
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s248850
Subject(s) - sorafenib , hepatocellular carcinoma , medicine , transcatheter arterial chemoembolization , gastroenterology , adverse effect , stage (stratigraphy) , progressive disease , liver cancer , oncology , chemotherapy , paleontology , biology
Transcatheter arterial chemoembolization (TACE) and targeted therapy have become common methods in the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC.